Featured Cover.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 495, doi. 10.1002/pst.2071
- Publication type:
- Article
Works matching IS 15391604 AND DT 2020 AND VI 19 AND IP 5
Results: 21
1
2
Methods for clarifying criteria for study continuation at interim analysis.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 720, doi. 10.1002/pst.2027
- By:
- Publication type:
- Article
3
Estimands and inference in cluster‐randomized vaccine trials.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 710, doi. 10.1002/pst.2026
- By:
- Publication type:
- Article
4
Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 692, doi. 10.1002/pst.2025
- By:
- Publication type:
- Article
5
Selection bias for treatments with positive Phase 2 results.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 679, doi. 10.1002/pst.2024
- By:
- Publication type:
- Article
6
Incorporating historical two‐arm data in clinical trials with binary outcome: A practical approach.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 662, doi. 10.1002/pst.2023
- By:
- Publication type:
- Article
7
Estimation of group means in generalized linear mixed models.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 646, doi. 10.1002/pst.2022
- By:
- Publication type:
- Article
8
Response to comments on "Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects" by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18:287‐303, DOI: 10.1002/pst.1923
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 736, doi. 10.1002/pst.2021
- By:
- Publication type:
- Article
9
Burden‐of‐illness vaccine efficacy.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 636, doi. 10.1002/pst.2020
- By:
- Publication type:
- Article
10
The attributable estimand: A new approach to account for intercurrent events.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 626, doi. 10.1002/pst.2019
- By:
- Publication type:
- Article
11
Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 613, doi. 10.1002/pst.2018
- By:
- Publication type:
- Article
12
Comments on "Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects" by Jose Jimenez, Viktoriya Stalbovskaya, and Byron Jones. Pharm Stat. 18:287‐303, 2019, DOI: 10.1002/pst.1923.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 733, doi. 10.1002/pst.2017
- By:
- Publication type:
- Article
13
Comment on Wages et al, Coherence principles in interval‐based dose finding. Pharmaceutical Statistics 2019, doi:10.1002/pst.1974.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 741, doi. 10.1002/pst.2016
- By:
- Publication type:
- Article
14
Comparison of response adaptive randomization features in multiarm clinical trials with control.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 602, doi. 10.1002/pst.2015
- By:
- Publication type:
- Article
15
Improving interim decisions in randomized trials by exploiting information on short‐term endpoints and prognostic baseline covariates.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 583, doi. 10.1002/pst.2014
- By:
- Publication type:
- Article
16
Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 561, doi. 10.1002/pst.2013
- By:
- Publication type:
- Article
17
A critical review of graphics for subgroup analyses in clinical trials.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 541, doi. 10.1002/pst.2012
- By:
- Publication type:
- Article
18
Combination of several matching adjusted indirect comparisons (MAICs) with an application in psoriasis.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 532, doi. 10.1002/pst.2011
- By:
- Publication type:
- Article
19
Revisit of test‐then‐pool methods and some practical considerations.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 498, doi. 10.1002/pst.2009
- By:
- Publication type:
- Article
20
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 496, doi. 10.1002/pst.1961
- Publication type:
- Article
21
Simultaneous confidence interval for assessing non‐inferiority with assay sensitivity in a three‐arm trial with binary endpoints.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 518, doi. 10.1002/pst.2010
- By:
- Publication type:
- Article